PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta (Q46252518)

20 December 2017

title

PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta (English)

1 reference

20 December 2017

0 references

Toru Kawai

1

1 reference

20 December 2017

Takao Masaki

2

1 reference

20 December 2017

Shigehiro Doi

3

1 reference

20 December 2017

Tetsuji Arakawa

4

1 reference

20 December 2017

Yukio Yokoyama

5

1 reference

20 December 2017

Toshiki Doi

6

1 reference

20 December 2017

Nobuoki Kohno

7

1 reference

20 December 2017

Noriaki Yorioka

8

1 reference

20 December 2017

publication date

10 November 2008

1 reference

20 December 2017

published in

Laboratory Investigation

1 reference

20 December 2017

volume

89

1 reference

20 December 2017

issue

1

1 reference

20 December 2017

page(s)

47-58

1 reference

20 December 2017

Molecular basis of renal fibrosis

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

Renal fibrosis: new insights into the pathogenesis and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

Pathogenesis of renal injury in obstructive uropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

Specific molecular targeting of renal injury in obstructive nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

The effect of high glucose and PPAR-gamma agonists on PPAR-gamma expression and function in HK-2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

Suppression of experimental crescentic glomerulonephritis by peroxisome proliferator-activated receptor (PPAR)? activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

Amelioration of anti-Thy1-glomerulonephritis by PPAR-gamma agonism without increase of endothelial progenitor cell homing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

PPARgamma ligand attenuates PDGF-induced mesangial cell proliferation: role of MAP kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

c-Fos-driven transcriptional activation of transforming growth factor β-1: inhibition of high glucose-induced promoter activity by thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

Activation of the ERK pathway precedes tubular proliferation in the obstructed rat kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

Angiotensin II induces fibronectin expression in human peritoneal mesothelial cells via ERK1/2 and p38 MAPK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

PDGF receptor tyrosine kinase inhibitor suppresses mesangial cell proliferation involving STAT3 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

Agonist of peroxisome proliferator-activated receptor-gamma, rosiglitazone, reduces renal injury and dysfunction in a murine sepsis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

Effects of different PPARgamma-agonists on MCP-1 expression and monocyte recruitment in experimental glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

Obstructive nephropathy and renal fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

Obstructive nephropathy: towards biomarker discovery and gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

Antibody to transforming growth factor-beta ameliorates tubular apoptosis in unilateral ureteral obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

Differentiation of human circulating fibrocytes as mediated by transforming growth factor-beta and peroxisome proliferator-activated receptor gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

Troglitazone's rapid and sustained activation of ERK1/2 induces cellular acidosis in LLC-PK1-F+ cells: physiological responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

15-Deoxy-delta 12,14-prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

Troglitazone and pioglitazone interactions via PPAR-gamma-independent and -dependent pathways in regulating physiological responses in renal tubule-derived cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

Transcriptional Regulation of Nephrin Gene by Peroxisome Proliferator-Activated Receptor- Agonist: Molecular Mechanism of the Antiproteinuric Effect of Pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

7 January 2021

Renal protective effect of troglitazone in Wistar fatty rats

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

7 January 2021

Protective effects of peroxisome proliferator-activated receptor gamma ligand on apoptosis and hepatocyte growth factor induction in renal ischemia-reperfusion injury

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

7 January 2021

Signal transducer and activator of transcription 3 involvement in the development of renal interstitial fibrosis after unilateral ureteral obstruction

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

7 January 2021

Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: a mechanism for activation of latent TGF-β1

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

7 January 2021

Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

7 January 2021

Quantification of TGF-beta1 mRNA along rat nephron in obstructive nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.104

7 January 2021

10.1038/LABINVEST.2008.104

Identifiers

DOI

1 reference

20 December 2017

1 reference

20 December 2017